Sanofi

Sanofi SNYNF Stock

$93.09   0.107537%
Add to favorites
Market Cap
$111.76B
LOW - HIGH [24H]
$95.00 - $95.00
VOLUME [24H]
$1.00K
P/E Ratio
23.15
Earnings per share
$4.02
ISIN
FR0000120578
Price   Prediction

Sanofi Price Chart

Sorry, that's all we've gotfor now...

Sanofi (SNYNF) stock price today is 93.09 USD on OTC Markets OTCPK (+0.11% on the day). Updated .

Sanofi SNYNF Financial and Trading Overview

Sanofi stock price 93.09 USD
Previous Close 92.99 USD
Open 95 USD
Bid 60.35 USD x 20000
Ask 133.37 USD x 20000
Day's Range 95 - 95 USD
52 Week Range 76.76 - 100 USD
Volume 1K USD
Avg. Volume 5.75K USD
Market Cap 111.76B USD
Beta (5Y Monthly) 0.256
PE Ratio (TTM) 23.156715
EPS (TTM) 4.02 USD
Forward Dividend & Yield 4.84 (5.19%)
Ex-Dividend Date May 5, 2026
1y Target Est N/A

SNYNF Valuation Measures

Enterprise Value 125.94B USD
Trailing P/E 23.156715
Forward P/E 10.063784
PEG Ratio (5 yr expected) 2.87
Price/Sales (ttm) 2.1922333
Price/Book (mrq) 1.3643824
Enterprise Value/Revenue 2.47
Enterprise Value/EBITDA 8.525

Trading Information

Sanofi Stock Price History

Beta (5Y Monthly) 0.256
52-Week Change -4.74%
S&P500 52-Week Change 3.06%
52 Week High 100 USD
52 Week Low 76.76 USD
50-Day Moving Average 85.44 USD
200-Day Moving Average 88.34 USD

SNYNF Share Statistics

Avg. Volume (3 month) 5.75K USD
Avg. Daily Volume (10-Days) 4.64K USD
Shares Outstanding 1.2B
Float 1.08B
Short Ratio N/A
% Held by Insiders 10.31%
% Held by Institutions 42.02%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield 405.99%
Payout Ratio 1.1908001
Last Split Factor 1005:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 8.19%
Operating Margin (ttm) 22.27%
Gross Margin 74.28%
EBITDA Margin 28.97%

Management Effectiveness

Return on Assets (ttm) 5.45%
Return on Equity (ttm) 5.71%

Income Statement

Revenue (ttm) 50.98B USD
Revenue Per Share (ttm) 42.37 USD
Quarterly Revenue Growth (yoy) 15.69%
Gross Profit (ttm) 37.87B USD
EBITDA 14.77B USD
Net Income Avi to Common (ttm) 4.14B USD
Diluted EPS (ttm) 4.02
Quarterly Earnings Growth (yoy) 7.79%

Balance Sheet

Total Cash (mrq) 5.97B USD
Total Cash Per Share (mrq) 4.97 USD
Total Debt (mrq) 19.84B USD
Total Debt/Equity (mrq) 27.1 USD
Current Ratio (mrq) 1.116
Book Value Per Share (mrq) 68.22867

Cash Flow Statement

Operating Cash Flow (ttm) 11.96B USD
Levered Free Cash Flow (ttm) 8.27B USD

Profile of Sanofi

Country United States
State N/A
City Paris
Address 46, avenue de la Grande ArmEe
ZIP 75017
Phone 33 1 53 77 40 00
Website https://www.sanofi.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 74846

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Q&A For Sanofi Stock

What is a current SNYNF stock price?

Sanofi SNYNF stock price today per share is 93.09 USD.

How to purchase Sanofi stock?

You can buy SNYNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Sanofi?

The stock symbol or ticker of Sanofi is SNYNF.

Which industry does the Sanofi company belong to?

The Sanofi industry is Drug Manufacturers - General.

How many shares does Sanofi have in circulation?

The max supply of Sanofi shares is 1.2B.

What is Sanofi Price to Earnings Ratio (PE Ratio)?

Sanofi PE Ratio is 23.15671500 now.

What was Sanofi earnings per share over the trailing 12 months (TTM)?

Sanofi EPS is 4.02 USD over the trailing 12 months.

Which sector does the Sanofi company belong to?

The Sanofi sector is Healthcare.

$2.07T
Total marketcap
$68.46B
Total volume
BTC 58.81%   •   ETH 10.04%
Dominance
Select currency